Applications of (R)-3-Amino-3-Phenylpropionic Acid Hydrochloride in Industrial Manufacturing

As a direct manufacturer of (R)-3-Amino-3-Phenylpropionic Acid Hydrochloride, we supply this chiral intermediate to specialized industries, where consistent purity, regulatory compliance, and application-specific performance are required. Below, we present key downstream manufacturing scenarios where our product is actively used, with detailed technical information tailored for each application pathway.

1. Chiral Active Pharmaceutical Ingredient (API) Synthesis

Pharmaceutical manufacturers routinely employ this compound as a key chiral intermediate for the construction of complex molecules in central nervous system (CNS) drug APIs. Its defined stereochemistry allows chemists to achieve desired enantiomeric purity in the final pharmaceutical products, helping to meet strict regulatory controls over impurity profiles in regulated markets.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU Regulation (EC) No 1223/2009 for APIs
• Ph. Eur. monographs for chiral precursors
• US FDA cGMP (21 CFR Parts 210 and 211)

Typical usage ratio

• 1.02–1.10 molar equivalents, precisely adjusted based on target API yield and impurity control

Downstream process integration

• Introduced during the early phase of the multi-step synthesis, involving amidation or reductive amination reactions to construct the API scaffold

Final product types

• Chiral CNS drug APIs (e.g., dopaminergic agents)
• Enantiomer-specific psychotropic drug substances

2. Peptide and Peptidomimetic Synthesis

In modern peptide chemistry, manufacturers use this raw material as a non-proteinogenic amino acid building block to modify peptide chains and enhance bioactivity or metabolic stability of therapeutic peptides. It enables precise insertion of chiral centers to improve pharmacokinetic properties and receptor selectivity of finished peptide products.

Industry compliance standards

• Good Manufacturing Practice (ICH Q7, EU GMP Part II)
• USP <1045> Biologics and Biotechnological Products
• Peptide monographs in JP, EP, USP
• ISO 13485 for medical device peptides (where applicable)

Typical usage ratio

• 1–5% of total amino acid content in peptide sequences, determined by desired modification and biological target specificity

Downstream process integration

• Directly coupled into peptide sequences via solid-phase peptide synthesis (SPPS) using Fmoc/Boc strategies, or introduced in solution-based peptide elongation steps

Final product types

• Modified peptide APIs for metabolic disorders
• Peptidomimetic research compounds
• Diagnostic or imaging peptides

3. Fine Chemical and Advanced Intermediate Manufacturing

Chemical producers in the specialty and fine chemicals industry incorporate this compound as a bespoke precursor to synthesize advanced intermediates containing chiral β-amino acid motifs. Its reliable supply and stereoselective nature support high-purity downstream transformation, enabling the creation of non-pharma specialty molecules for further chemical elaboration.

Industry compliance standards

• REACH Regulation (EC) No 1907/2006 for intermediates
• ISO 9001:2015 certified quality management systems
• Environmental and occupational safety as per local legislation (e.g., HSE, OSHA)
• Purity and traceability documentation per customer-specific requirements

Typical usage ratio

• 1.05–1.20 equivalents per synthetic step, fine-tuned by reaction optimization for yield and purity maximization

Downstream process integration

• Used as an initial chiral feedstock for condensation, cyclization, or ring-closure reactions in custom synthesis routes

Final product types

• Chiral fine chemical intermediates
• β-lactam ring system building blocks
• Functionalized specialty heterocycles for further functionalization

4. Chiral Auxiliary for Asymmetric Synthesis in Research & Development

Pharmaceutical R&D and chemical innovation labs leverage this compound as an enantiomerically pure auxiliary to direct the formation of new stereocenters during asymmetric transformations. Its integration in pilot and process development provides a reliable route for asymmetric catalysis studies and rapid generation of lead candidates or patentable analogs.

Industry compliance standards

• US FDA GLP (21 CFR Part 58) for preclinical research
• OECD Principles of Good Laboratory Practice
• Internal QA/QC for research compounds
• Material Safety Data Sheet (MSDS) compliance

Typical usage ratio

• 0.5–1.5 equivalents relative to target substrate, protocol selection bases ratio on desired stereoselectivity and product outcome

Downstream process integration

• Added as a chiral auxiliary or catalyst in asymmetric hydrogenation or alkylation reactions within small-batch lab or pilot-scale setups

Final product types

• Stereochemically pure intermediates for early-stage drug discovery
• Chiral reference standards
• Patented analogs for pharmaceutical R&D libraries